Angiogenesis in the atherosclerotic plaque

Redox Biology

Volumn 12, Issue , 2017, Pages 18-34

  Camaré, Caroline ^a,b,c   Pucelle, Mélanie ^a   Nègre Salvayre, Anne ^a   Salvayre, Robert ^a,b,c  

^a Université de Toulouse   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU RANGUEIL   (France)

Author keywords

Angiogenesis; Atherosclerosis; Hypercholesterolemia; Neovascularization; VEGF

Indexed keywords

ALDEHYDE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR; METALLOPROTEINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL RESEARCH; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; FATTY ACID OXIDATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOXIA; INFLAMMATION; INFLAMMATORY CELL; MALIGNANT NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; REVIEW; THROMBOEMBOLISM; WESTERN HEMISPHERE; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; METABOLISM; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC;

EID: 85012306563     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.01.007     Document Type: Review

References (322)

1. [1] Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:6423 (1993), 801–809.
2. [2] Lusis, A.J., Atherosclerosis. Nature 407:6801 (2000), 233–241.
3. [3] Libby, P., Inflammation in atherosclerosis. Nature 420:6917 (2002), 868–874.
4. [4] Michel, J.B., Thaunat, O., Houard, X., Meilhac, O., Caligiuri, G., Nicoletti, A., Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb. Vasc. Biol. 27:6 (2007), 1259–1268.
5. [5] Michel, J.B., Martin-Ventura, J.L., Nicoletti, A., Ho-Tin-Noe, B., Pathology of human plaque vulnerability: mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 234:2 (2014), 311–319.
6. [6] Vaklavas, C., Lenihan, D., Kurzrock, R., Tsimberidou, A.M., Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist 15:2 (2010), 130–141.
7. [7] Tian, J., Hu, S., Sun, Y., Yu, H., Han, X., Cheng, W., Ban, X., Zhang, S., Yu, B., Jang, I.K., Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast-enhanced ultrasound imaging and intravascular ultrasound study. Heart 99:1 (2013), 48–54.
8. [8] Katsi, V., Zerdes, I., Manolakou, S., Makris, T., Nihoyannopoulos, P., Tousoulis, D., Kallikazaros, I., Anti-VEGF Anticancer Drugs: mind the Hypertension. Recent Adv. Cardiovasc Drug Disco. 9:2 (2014), 63–72.
9. [9] Stary, H.C., Chandler, A.B., Dinsmore, R.E., Fuster, V., Glagov, S., Insull, W. Jr., Rosenfeld, M.E., Schwartz, C.J., Wagner, W.D., Wissler, R.W., A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. Am. Heart Assoc. Circ. 92:5 (1995), 1355–1374.
10. [10] Otsuka, F., Kramer, M.C., Woudstra, P., Yahagi, K., Ladich, E., Finn, A.V., de Winter, R.J., Kolodgie, F.D., Wight, T.N., Davis, H.R., Joner, M., Virmani, R., Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: a pathology study. Atherosclerosis 241:2 (2015), 772–782.
11. [11] Yahagi, K., Kolodgie, F.D., Otsuka, F., Finn, A.V., Davis, H.R., Joner, M., Virmani, R., Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat. Rev. Cardiol. 13:2 (2016), 79–98.
12. [12] Insull, W. Jr., The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am. J. Med 122:1 Suppl (2009), S3–S14.
13. [13] Moreno, P.R., Purushothaman, K.R., Sirol, M., Levy, A.P., Fuster, V., Neovascularization in human atherosclerosis. Circulation 113:18 (2006), 2245–2252.
14. [14] Koester, W., Endarteritis and arteritis. Berl. Klin. Woche. 13 (1876), 454–455.
15. [15] Winternitz, M.C., Thomas, R.M., LeCompte, P.M., The Biology of Arteriosclerosis. 1938, C. Thomas Pub, Springfield, IL.
16. [16] Geiringer, E., Intimal vascularization and atherosclerosis. J. Pathol. Bacteriol. 63:2 (1951), 201–211.
17. [17] Sueishi, K., Yonemitsu, Y., Nakagawa, K., Kaneda, Y., Kumamoto, M., Nakashima, Y., Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann. NY Acad. Sci. 811 (1997), 322–324.
18. [18] Ritman, E.L., Lerman, A., The dynamic vasa vasorum. Cardiovasc. Res. 75:4 (2007), 649–658.
19. [19] Kwon, H.M., Sangiorgi, G., Ritman, E.L., McKenna, C., Holmes, D.R. Jr., Schwartz, R.S., Lerman, A., Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J. Clin. Invest. 101:8 (1998), 1551–1556.
20. [20] Bhardwaj, S., Roy, H., Heikura, T., Yla-Herttuala, S., VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur. J. Clin. Invest. 35:11 (2005), 669–676.
21. [21] Moulton, K.S., Heller, E., Konerding, M.A., Flynn, E., Palinski, W., Folkman, J., Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99:13 (1999), 1726–1732.
22. [22] Gossl, M., Herrmann, J., Tang, H., Versari, D., Galili, O., Mannheim, D., Rajkumar, S.V., Lerman, L.O., Lerman, A., Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. Basic Res Cardiol. 104:6 (2009), 695–706.
23. [23] Kolodgie, F.D., Gold, H.K., Burke, A.P., Fowler, D.R., Kruth, H.S., Weber, D.K., Farb, A., Guerrero, L.J., Hayase, M., Kutys, R., Narula, J., Finn, A.V., Virmani, R., Intraplaque hemorrhage and progression of coronary atheroma. N. Engl. J. Med. 349:24 (2003), 2316–2325.
24. [24] Conway, E.M., Collen, D., Carmeliet, P., Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49:3 (2001), 507–521.
25. [25] Simons, M., Angiogenesis: where do we stand now?. Circulation 111:12 (2005), 1556–1566.
26. [26] Tanaka, K., Nagata, D., Hirata, Y., Tabata, Y., Nagai, R., Sata, M., Augmented angiogenesis in adventitia promotes growth of atherosclerotic plaque in apolipoprotein E-deficient mice. Atherosclerosis 215:2 (2011), 366–373.
27. [27] Carmeliet, P., Angiogenesis in health and disease. Nat. Med 9:6 (2003), 653–660.
28. [28] Sluimer, J.C., Daemen, M.J., Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J. Pathol. 218:1 (2009), 7–29.
29. [29] Marsch, E., Sluimer, J.C., Daemen, M.J., Hypoxia in atherosclerosis and inflammation. Curr. Opin. Lipido. 24:5 (2013), 393–400.
30. [30] Moreno, P.R., Purushothaman, M., Purushothaman, K.R., Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. Ann. NY Acad. Sci. 1254 (2012), 7–17.
31. [31] Potente, M., Gerhardt, H., Carmeliet, P., Basic and therapeutic aspects of angiogenesis. Cell 146:6 (2011), 873–887.
32. [32] Horowitz, A., Simons, M., Branching morphogenesis. Circ. Res. 103:8 (2008), 784–795.
33. [33] Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473:7347 (2011), 298–307.
34. [34] Small, J.V., Stradal, T., Vignal, E., Rottner, K., The lamellipodium: where motility begins. Trends Cell Biol. 12:3 (2002), 112–120.
35. [35] van Hinsbergh, V.W., Koolwijk, P., Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 78:2 (2008), 203–212.
36. [36] Blanco, R., Gerhardt, H., VEGF and Notch in tip and stalk cell selection. Cold Spring Harb. Perspect. Med., 3(1), 2013, a006569.
37. [37] Suchting, S., Freitas, C., le Noble, F., Benedito, R., Breant, C., Duarte, A., Eichmann, A., The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. USA 104:9 (2007), 3225–3230.
38. [38] Carmeliet, P., De Smet, F., Loges, S., Mazzone, M., Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat. Rev. Clin. Oncol. 6:6 (2009), 315–326.
39. [39] Habeck, H., Vogel, A.M., Schulte-Merker, S., Getting connected. Dev. Cell 5:5 (2003), 669–670.
40. [40] Urbich, C., Dimmeler, S., Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 14:8 (2004), 318–322.
41. [41] Ho-Tin-Noe, B., Michel, J.B., Initiation of angiogenesis in atherosclerosis: smooth muscle cells as mediators of the angiogenic response to atheroma formation. Trends Cardiovasc. Med. 21:7 (2011), 183–187.
42. [42] Cheng, C., Chrifi, I., Pasterkamp, G., Duckers, H.J., Biological mechanisms of microvessel formation in advanced atherosclerosis: the big five. Trends Cardiovasc. Med. 23:5 (2013), 153–164.
43. [43] Eelen, G., de Zeeuw, P., Simons, M., Carmeliet, P., Endothelial cell metabolism in normal and diseased vasculature. Circ. Res. 116:7 (2015), 1231–1244.
44. [44] Pugh, C.W., Ratcliffe, P.J., Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9:6 (2003), 677–684.
45. [45] Semenza, G.L., Wang, G.L., A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12:12 (1992), 5447–5454.
46. [46] Huang, L.E., Gu, J., Schau, M., Bunn, H.F., Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95:14 (1998), 7987–7992.
47. [47] Wenger, R.H., Cellular adaptation to hypoxia: o2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 16:10 (2002), 1151–1162.
48. [48] Semenza, G.L., Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiol. (Bethesda) 19 (2004), 176–182.
49. [49] Berra, E., Ginouves, A., Pouyssegur, J., The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 7:1 (2006), 41–45.
50. [50] van Uden, P., Kenneth, N.S., Rocha, S., Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem. J. 412:3 (2008), 477–484.
51. [51] Wenger, R.H., Stiehl, D.P., Camenisch, G., Integration of oxygen signaling at the consensus HRE. Sci. STKE, 2005(306), 2005, re12.
52. [52] Hirota, K., Semenza, G.L., Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59:1 (2006), 15–26.
53. [53] Frede, S., Berchner-Pfannschmidt, U., Fandrey, J., Regulation of hypoxia-inducible factors during inflammation. Methods Enzym. 435 (2007), 405–419.
54. −/− mice. Atherosclerosis 233:2 (2014), 641–647.
55. [55] Rahtu-Korpela, L., Maatta, J., Dimova, E.Y., Horkko, S., Gylling, H., Walkinshaw, G., Hakkola, J., Kivirikko, K.I., Myllyharju, J., Serpi, R., Koivunen, P., Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 36:4 (2016), 608–617.
56. [56] Marsch, E., Demandt, J.A., Theelen, T.L., Tullemans, B.M., Wouters, K., Boon, M.R., van Dijk, T.H., Gijbels, M.J., Dubois, L.J., Meex, S.J., Mazzone, M., Hung, G., Fisher, E.A., Biessen, E.A., Daemen, M.J., Rensen, P.C., Carmeliet, P., Groen, A.K., Sluimer, J.C., Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. Eur. Heart J., 2016.
57. −/− mice. Biochem. Biophys. Res. Commun. 473:1 (2016), 99–106.
58. [58] Greenblatt, M., Shubi, P., Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl. Cancer Inst. 41:1 (1968), 111–124.
59. [59] Ehrmann, R.L., Knoth, M., Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J. Natl. Cancer Inst. 41:6 (1968), 1329–1341.
60. [60] Folkman, J., Merler, E., Abernathy, C., Williams, G., Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133:2 (1971), 275–288.
61. [61] Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:4587 (1983), 983–985.
62. [62] Keck, P.J., Hauser, S.D., Krivi, G., Sanzo, K., Warren, T., Feder, J., Connolly, D.T., Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:4935 (1989), 1309–1312.
63. [63] Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:4935 (1989), 1306–1309.
64. [64] Plouet, J., Schilling, J., Gospodarowicz, D., Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J. 8:12 (1989), 3801–3806.
65. [65] Ferrara, N., Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25:4 (2004), 581–611.
66. [66] Holmes, D.I., Zachary, I., The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol., 6(2), 2005, 209.
67. [67] Kipryushina, Y.O., Yakovlev, K.V., Odintsova, N.A., Vascular endothelial growth factors: a comparison between invertebrates and vertebrates. Cytokine Growth Factor Rev. 26:6 (2015), 687–695.
68. [68] Vitt, U.A., Hsu, S.Y., Hsueh, A.J., Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol. Endocrinol. 15:5 (2001), 681–694.
69. [69] Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J.C., Abraham, J.A., The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:18 (1991), 11947–11954.
70. [70] Ferrara, N., Gerber, H.P., LeCouter, J., The biology of VEGF and its receptors. Nat. Med. 9:6 (2003), 669–676.
71. [71] Arcondeguy, T., Lacazette, E., Millevoi, S., Prats, H., Touriol, C., VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res. 41:17 (2013), 7997–8010.
72. [72] Takahashi, H., Shibuya, M., The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond.) 109:3 (2005), 227–241.
73. [73] Harper, S.J., Bates, D.O., VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat. Rev. Cancer 8:11 (2008), 880–887.
74. [74] Shweiki, D., Itin, A., Soffer, D., Keshet, E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:6398 (1992), 843–845.
75. [75] Pages, G., Pouyssegur, J., Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc. Res. 65:3 (2005), 564–573.
76. [76] Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., Nagy, A., Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:6573 (1996), 435–439.
77. [77] Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K.J., Moore, M.W., Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:6573 (1996), 439–442.
78. [78] Holm, P.W., Slart, R.H., Zeebregts, C.J., Hillebrands, J.L., Tio, R.A., Atherosclerotic plaque development and instability: a dual role for VEGF. Ann. Med. 41:4 (2009), 257–264.
79. [79] Asahara, T., Chen, D., Tsurumi, Y., Kearney, M., Rossow, S., Passeri, J., Symes, J.F., Isner, J.M., Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 94:12 (1996), 3291–3302.
80. [80] Kim, I., Moon, S.O., Kim, S.H., Kim, H.J., Koh, Y.S., Koh, G.Y., Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J. Biol. Chem. 276:10 (2001), 7614–7620.
81. [81] Marumo, T., Schini-Kerth, V.B., Busse, R., Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 48:5 (1999), 1131–1137.
82. [82] Barleon, B., Sozzani, S., Zhou, D., Weich, H.A., Mantovani, A., Marme, D., Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:8 (1996), 3336–3343.
83. [83] Heinonen, S.E., Kivela, A.M., Huusko, J., Dijkstra, M.H., Gurzeler, E., Makinen, P.I., Leppanen, P., Olkkonen, V.M., Eriksson, U., Jauhiainen, M., Yla-Herttuala, S., The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models. Cardiovasc. Res. 99:4 (2013), 716–723.
84. [84] Inoue, M., Itoh, H., Ueda, M., Naruko, T., Kojima, A., Komatsu, R., Doi, K., Ogawa, Y., Tamura, N., Takaya, K., Igaki, T., Yamashita, J., Chun, T.H., Masatsugu, K., Becker, A.E., Nakao, K., Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:20 (1998), 2108–2116.
85. [85] Celletti, F.L., Waugh, J.M., Amabile, P.G., Brendolan, A., Hilfiker, P.R., Dake, M.D., Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 7:4 (2001), 425–429.
86. [86] Zhao, Q., Egashira, K., Inoue, S., Usui, M., Kitamoto, S., Ni, W., Ishibashi, M., Hiasa Ki, K., Ichiki, T., Shibuya, M., Takeshita, A., Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105:9 (2002), 1110–1115.
87. [87] Leppanen, P., Koota, S., Kholova, I., Koponen, J., Fieber, C., Eriksson, U., Alitalo, K., Yla-Herttuala, S., Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 112:9 (2005), 1347–1352.
88. [88] Giacca, M., Zacchigna, S., VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 19:6 (2012), 622–629.
89. [89] Rubanyi, G.M., Angiogenic gene therapy for refractory angina. Expert Opin. Biol. Ther. 16:3 (2016), 303–315.
90. [90] Faruque, L.I., Lin, M., Battistella, M., Wiebe, N., Reiman, T., Hemmelgarn, B., Thomas, C., Tonelli, M., Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One, 9(7), 2014, e101145.
91. [91] Grimmond, S., Lagercrantz, J., Drinkwater, C., Silins, G., Townson, S., Pollock, P., Gotley, D., Carson, E., Rakar, S., Nordenskjold, M., Ward, L., Hayward, N., Weber, G., Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 6:2 (1996), 124–131.
92. [92] Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., Orpana, A., Pettersson, R.F., Alitalo, K., Eriksson, U., Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA 93:6 (1996), 2576–2581.
93. [93] Bry, M., Kivela, R., Leppanen, V.M., Alitalo, K., Vascular endothelial growth factor-B in physiology and disease. Physiol. Rev. 94:3 (2014), 779–794.
94. [94] Bellomo, D., Headrick, J.P., Silins, G.U., Paterson, C.A., Thomas, P.S., Gartside, M., Mould, A., Cahill, M.M., Tonks, I.D., Grimmond, S.M., Townson, S., Wells, C., Little, M., Cummings, M.C., Hayward, N.K., Kay, G.F., Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86:2 (2000), E29–E35.
95. [95] Hagberg, C.E., Falkevall, A., Wang, X., Larsson, E., Huusko, J., Nilsson, I., van Meeteren, L.A., Samen, E., Lu, L., Vanwildemeersch, M., Klar, J., Genove, G., Pietras, K., Stone-Elander, S., Claesson-Welsh, L., Yla-Herttuala, S., Lindahl, P., Eriksson, U., Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464:7290 (2010), 917–921.
96. [96] Robciuc, M.R., Kivela, R., Williams, I.M., de Boer, J.F., van Dijk, T.H., Elamaa, H., Tigistu-Sahle, F., Molotkov, D., Leppanen, V.M., Kakela, R., Eklund, L., Wasserman, D.H., Groen, A.K., Alitalo, K., VEGFB/VEGFR1-Induced Expansion of Adipose Vasculature Counteracts Obesity and Related Metabolic Complications. Cell Metab. 23:4 (2016), 712–724.
97. [97] Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P., Persico, M.G., Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA 88:20 (1991), 9267–9271.
98. [98] Dewerchin, M., Carmeliet, P., PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb. Perspect. Med, 2(8), 2012.
99. [99] De Falco, S., The discovery of placenta growth factor and its biological activity. Exp. Mol. Med 44:1 (2012), 1–9.
100. [100] Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., DiPalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., VandenDriessche, T., Ponten, A., Eriksson, U., Plate, K.H., Foidart, J.M., Schaper, W., Charnock-Jones, D.S., Hicklin, D.J., Herbert, J.M., Collen, D., Persico, M.G., Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:5 (2001), 575–583.
101. [101] Khurana, R., Moons, L., Shafi, S., Luttun, A., Collen, D., Martin, J.F., Carmeliet, P., Zachary, I.C., Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 111:21 (2005), 2828–2836.
102. [102] Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksela, O., Kalkkinen, N., Alitalo, K., Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16:13 (1997), 3898–3911.
103. [103] Dashkevich, A., Hagl, C., Beyersdorf, F., Nykanen, A.I., Lemstrom, K.B., VEGF Pathways in the Lymphatics of Healthy and Diseased Heart. Microcirculation 23:1 (2016), 5–14.
104. [104] Karkkainen, M.J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T.V., Jeltsch, M., Jackson, D.G., Talikka, M., Rauvala, H., Betsholtz, C., Alitalo, K., Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5:1 (2004), 74–80.
105. [105] Baldwin, M.E., Halford, M.M., Roufail, S., Williams, R.A., Hibbs, M.L., Grail, D., Kubo, H., Stacker, S.A., Achen, M.G., Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol. Cell Biol. 25:6 (2005), 2441–2449.
106. [106] Dumont, D.J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M., Alitalo, K., Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282:5390 (1998), 946–949.
107. [107] Haiko, P., Makinen, T., Keskitalo, S., Taipale, J., Karkkainen, M.J., Baldwin, M.E., Stacker, S.A., Achen, M.G., Alitalo, K., Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell Biol. 28:15 (2008), 4843–4850.
108. [108] Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R.K., Alitalo, K., Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:5317 (1997), 1423–1425.
109. [109] Lim, H.Y., Thiam, C.H., Yeo, K.P., Bisoendial, R., Hii, C.S., McGrath, K.C., Tan, K.W., Heather, A., Alexander, J.S., Angeli, V., Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL. Cell Metab. 17:5 (2013), 671–684.
110. [110] Martel, C., Li, W., Fulp, B., Platt, A.M., Gautier, E.L., Westerterp, M., Bittman, R., Tall, A.R., Chen, S.H., Thomas, M.J., Kreisel, D., Swartz, M.A., Sorci-Thomas, M.G., Randolph, G.J., Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J. Clin. Invest 123:4 (2013), 1571–1579.
111. [111] Vuorio, T., Nurmi, H., Moulton, K., Kurkipuro, J., Robciuc, M.R., Ohman, M., Heinonen, S.E., Samaranayake, H., Heikura, T., Alitalo, K., Yla-Herttuala, S., Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis. Arterioscler Thromb. Vasc. Biol. 34:6 (2014), 1162–1170.
112. [112] Aspelund, A., Robciuc, M.R., Karaman, S., Makinen, T., Alitalo, K., Lymphatic System in Cardiovascular Medicine. Circ. Res. 118:3 (2016), 515–530.
113. [113] de Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., Williams, L.T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:5047 (1992), 989–991.
114. [114] Terman, B.I., Dougher-Vermazen, M., Carrion, M.E., Dimitrov, D., Armellino, D.C., Gospodarowicz, D., Bohlen, P., Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys. Res. Commun. 187:3 (1992), 1579–1586.
115. [115] Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., Klagsbrun, M., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:6 (1998), 735–745.
116. [116] Claesson-Welsh, L., VEGF receptor signal transduction - A brief update. Vasc. Pharm., 2016.
117. [117] Koch, S., Claesson-Welsh, L., Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med., 2(7), 2012, a006502.
118. [118] Shibuya, M., Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 153:1 (2013), 13–19.
119. [119] Hoeben, A., Landuyt, B., Highley, M.S., Wildiers, H., Van Oosterom, A.T., Bruijn, E.A. De, Vascular endothelial growth factor and angiogenesis. Pharm. Rev. 56:4 (2004), 549–580.
120. [120] Simons, M., Gordon, E., Claesson-Welsh, L., Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol., 2016.
121. [121] Cudmore, M.J., Hewett, P.W., Ahmad, S., Wang, K.Q., Cai, M., Al-Ani, B., Fujisawa, T., Ma, B., Sissaoui, S., Ramma, W., Miller, M.R., Newby, D.E., Gu, Y., Barleon, B., Weich, H., Ahmed, A., The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat. Commun., 3, 2012, 972.
122. [122] Fong, G.H., Rossant, J., Gertsenstein, M., Breitman, M.L., Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:6535 (1995), 66–70.
123. [123] Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., Shibuya, M., Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95:16 (1998), 9349–9354.
124. [124] Zhao, Q., Egashira, K., Hiasa, K., Ishibashi, M., Inoue, S., Ohtani, K., Tan, C., Shibuya, M., Takeshita, A., Sunagawa, K., Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb. Vasc. Biol. 24:12 (2004), 2284–2289.
125. [125] Usui, R., Shibuya, M., Ishibashi, S., Maru, Y., Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep. 8:12 (2007), 1155–1161.
126. [126] Shibuya, M., Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9:4 (2006), 225–230 (discussion 231).
127. [127] Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F., Breitman, M.L., Schuh, A.C., Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:6535 (1995), 62–66.
128. [128] Winnik, S., Lohmann, C., Siciliani, G., von Lukowicz, T., Kuschnerus, K., Kraenkel, N., Brokopp, C.E., Enseleit, F., Michels, S., Ruschitzka, F., Luscher, T.F., Matter, C.M., Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis-implications for cardiovascular safety. Int J. Cardiol. 168:3 (2013), 2453–2461.
129. [129] Petrovan, R.J., Kaplan, C.D., Reisfeld, R.A., Curtiss, L.K., DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb. Vasc. Biol. 27:5 (2007), 1095–1100.
130. [130] Hauer, A.D., van Puijvelde, G.H., Peterse, N., de Vos, P., van Weel, V., van Wanrooij, E.J., Biessen, E.A., Quax, P.H., Niethammer, A.G., Reisfeld, R.A., van Berkel, T.J., Kuiper, J., Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb. Vasc. Biol. 27:9 (2007), 2050–2057.
131. [131] Choueiri, T.K., Schutz, F.A., Je, Y., Rosenberg, J.E., Bellmunt, J., Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 28:13 (2010), 2280–2285.
132. [132] Dumont, D.J., Yamaguchi, T.P., Conlon, R.A., Rossant, J., Breitman, M.L., tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7:8 (1992), 1471–1480.
133. [133] Partanen, J., Armstrong, E., Makela, T.P., Korhonen, J., Sandberg, M., Renkonen, R., Knuutila, S., Huebner, K., Alitalo, K., A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell Biol. 12:4 (1992), 1698–1707.
134. [134] Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Jain, V., Ryan, T.E., Bruno, J., Radziejewski, C., Maisonpierre, P.C., Yancopoulos, G.D., Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:7 (1996), 1161–1169.
135. [135] Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N., Daly, T.J., Davis, S., Sato, T.N., Yancopoulos, G.D., Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:5322 (1997), 55–60.
136. [136] Hanahan, D., Signaling vascular morphogenesis and maintenance. Science 277:5322 (1997), 48–50.
137. [137] Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., Holash, J., Vascular-specific growth factors and blood vessel formation. Nature 407:6801 (2000), 242–248.
138. [138] Thurston, G., Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res. 314:1 (2003), 61–68.
139. [139] Augustin, H.G., Koh, G.Y., Thurston, G., Alitalo, K., Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 10:3 (2009), 165–177.
140. [140] Moss, A., The angiopoietin: tie 2 interaction: a potential target for future therapies in human vascular disease. Cytokine Growth Factor Rev. 24:6 (2013), 579–592.
141. [141] Dumont, D.J., Gradwohl, G., Fong, G.H., Puri, M.C., Gertsenstein, M., Auerbach, A., Breitman, M.L., Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8:16 (1994), 1897–1909.
142. [142] Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N., Yancopoulos, G.D., Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:7 (1996), 1171–1180.
143. [143] Suri, C., McClain, J., Thurston, G., McDonald, D.M., Zhou, H., Oldmixon, E.H., Sato, T.N., Yancopoulos, G.D., Increased vascularization in mice overexpressing angiopoietin-1. Science 282:5388 (1998), 468–471.
144. [144] Gale, N.W., Thurston, G., Hackett, S.F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M.H., Jackson, D., Suri, C., Campochiaro, P.A., Wiegand, S.J., Yancopoulos, G.D., Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 3:3 (2002), 411–423.
145. [145] Puri, M.C., Rossant, J., Alitalo, K., Bernstein, A., Partanen, J., The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14:23 (1995), 5884–5891.
146. [146] Sato, T.N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., Qin, Y., Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:6535 (1995), 70–74.
147. [147] Nykanen, A.I., Krebs, R., Saaristo, A., Turunen, P., Alitalo, K., Yla-Herttuala, S., Koskinen, P.K., Lemstrom, K.B., Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107:9 (2003), 1308–1314.
148. [148] Ahmed, A., Fujisawa, T., Multiple roles of angiopoietins in atherogenesis. Curr. Opin. Lipido. 22:5 (2011), 380–385.
149. [149] Theelen, T.L., Lappalainen, J.P., Sluimer, J.C., Gurzeler, E., Cleutjens, J.P., Gijbels, M.J., Biessen, E.A., Daemen, M.J., Alitalo, K., Yla-Herttuala, S., Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. Atherosclerosis 241:2 (2015), 297–304.
150. [150] Post, S., Peeters, W., Busser, E., Lamers, D., Sluijter, J.P., Goumans, M.J., de Weger, R.A., Moll, F.L., Doevendans, P.A., Pasterkamp, G., Vink, A., Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J. Vasc. Res. 45:3 (2008), 244–250.
151. [151] Hauer, A.D., Habets, K.L., van Wanrooij, E.J., de Vos, P., Krueger, J., Reisfeld, R.A., van Berkel, T.J., Kuiper, J., Vaccination against TIE2 reduces atherosclerosis. Atherosclerosis 204:2 (2009), 365–371.
152. [152] Woo, K.V., Qu, X., Babaev, V.R., Linton, M.F., Guzman, R.J., Fazio, S., Baldwin, H.S., Tie1 attenuation reduces murine atherosclerosis in a dose-dependent and shear stress-specific manner. J. Clin. Invest 121:4 (2011), 1624–1635.
153. [153] Farhat, N., Thorin-Trescases, N., Mamarbachi, M., Villeneuve, L., Yu, C., Martel, C., Duquette, N., Gayda, M., Nigam, A., Juneau, M., Allen, B.G., Thorin, E., Angiopoietin-like 2 promotes atherogenesis in mice. J. Am. Heart Assoc., 2(3), 2013, e000201.
154. [154] Horio, E., Kadomatsu, T., Miyata, K., Arai, Y., Hosokawa, K., Doi, Y., Ninomiya, T., Horiguchi, H., Endo, M., Tabata, M., Tazume, H., Tian, Z., Takahashi, O., Terada, K., Takeya, M., Hao, H., Hirose, N., Minami, T., Suda, T., Kiyohara, Y., Ogawa, H., Kaikita, K., Oike, Y., Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Arterioscler Thromb. Vasc. Biol. 34:4 (2014), 790–800.
155. [155] Furchgott, R.F., Zawadzki, J.V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:5789 (1980), 373–376.
156. [156] Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., Chaudhuri, G., Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 84:24 (1987), 9265–9269.
157. [157] Palmer, R.M., Ferrige, A.G., Moncada, S., Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:6122 (1987), 524–526.
158. [158] Alderton, W.K., Cooper, C.E., Knowles, R.G., Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357:Pt 3 (2001), 593–615.
159. [159] Cooke, J.P., NO and angiogenesis. Atheroscler. Suppl. 4:4 (2003), 53–60.
160. [160] Forstermann, U., Sessa, W.C., Nitric oxide synthases: regulation and function. Eur. Heart J. 33:7 (2012), 829–837 (837a-837d).
161. [161] Vanhoutte, P.M., Zhao, Y., Xu, A., Leung, S.W., Thirty Years of Saying NO: sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. Circ. Res. 119:2 (2016), 375–396.
162. [162] Huang, P.L., Dawson, T.M., Bredt, D.S., Snyder, S.H., Fishman, M.C., Targeted disruption of the neuronal nitric oxide synthase gene. Cell 75:7 (1993), 1273–1286.
163. [163] Morishita, T., Tsutsui, M., Shimokawa, H., Horiuchi, M., Tanimoto, A., Suda, O., Tasaki, H., Huang, P.L., Sasaguri, Y., Yanagihara, N., Nakashima, Y., Vasculoprotective roles of neuronal nitric oxide synthase. FASEB J. 16:14 (2002), 1994–1996.
164. [164] Huang, P.L., Huang, Z., Mashimo, H., Bloch, K.D., Moskowitz, M.A., Bevan, J.A., Fishman, M.C., Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:6546 (1995), 239–242.
165. [165] Kuhlencordt, P.J., Gyurko, R., Han, F., Scherrer-Crosbie, M., Aretz, T.H., Hajjar, R., Picard, M.H., Huang, P.L., Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104:4 (2001), 448–454.
166. [166] Jang, J.J., Ho, H.K., Kwan, H.H., Fajardo, L.F., Cooke, J.P., Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation 102:12 (2000), 1414–1419.
167. [167] MacMicking, J.D., Nathan, C., Hom, G., Chartrain, N., Fletcher, D.S., Trumbauer, M., Stevens, K., Xie, Q.W., Sokol, K., Hutchinson, N., et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:4 (1995), 641–650.
168. [168] Wei, X.Q., Charles, I.G., Smith, A., Ure, J., Feng, G.J., Huang, F.P., Xu, D., Muller, W., Moncada, S., Liew, F.Y., Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:6530 (1995), 408–411.
169. [169] Laubach, V.E., Shesely, E.G., Smithies, O., Sherman, P.A., Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA 92:23 (1995), 10688–10692.
170. [170] Mungrue, I.N., Gros, R., You, X., Pirani, A., Azad, A., Csont, T., Schulz, R., Butany, J., Stewart, D.J., Husain, M., Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J. Clin. Invest 109:6 (2002), 735–743.
171. [171] Kuhlencordt, P.J., Hotten, S., Schodel, J., Rutzel, S., Hu, K., Widder, J., Marx, A., Huang, P.L., Ertl, G., Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice. Arterioscler Thromb. Vasc. Biol. 26:7 (2006), 1539–1544.
172. [172] Liu, V.W., Huang, P.L., Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc. Res. 77:1 (2008), 19–29.
173. [173] van Haperen, R., de Waard, M., van Deel, E., Mees, B., Kutryk, M., van Aken, T., Hamming, J., Grosveld, F., Duncker, D.J., de Crom, R., Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J. Biol. Chem. 277:50 (2002), 48803–48807.
174. [174] Kuhlencordt, P.J., Chen, J., Han, F., Astern, J., Huang, P.L., Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103:25 (2001), 3099–3104.
175. [175] Nakata, S., Tsutsui, M., Shimokawa, H., Suda, O., Morishita, T., Shibata, K., Yatera, Y., Sabanai, K., Tanimoto, A., Nagasaki, M., Tasaki, H., Sasaguri, Y., Nakashima, Y., Otsuji, Y., Yanagihara, N., Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 117:17 (2008), 2211–2223.
176. [176] Shimokawa, H., Tsutsui, M., Nitric oxide synthases in the pathogenesis of cardiovascular disease: lessons from genetically modified mice. Pflug. Arch. 459:6 (2010), 959–967.
177. [177] Wohlfart, P., Xu, H., Endlich, A., Habermeier, A., Closs, E.I., Hubschle, T., Mang, C., Strobel, H., Suzuki, T., Kleinert, H., Forstermann, U., Ruetten, H., Li, H., Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J. Pharm. Exp. Ther. 325:2 (2008), 370–379.
178. [178] Sharma, A., Sellers, S., Stefanovic, N., Leung, C., Tan, S.M., Huet, O., Granville, D.J., Cooper, M.E., de Haan, J.B., Bernatchez, P., Direct endothelial nitric oxide synthase activation provides atheroprotection in diabetes-accelerated atherosclerosis. Diabetes 64:11 (2015), 3937–3950.
179. [179] Fulton, D., Gratton, J.P., McCabe, T.J., Fontana, J., Fujio, Y., Walsh, K., Franke, T.F., Papapetropoulos, A., Sessa, W.C., Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399:6736 (1999), 597–601.
180. [180] Dimmeler, S., Zeiher, A.M., Akt takes center stage in angiogenesis signaling. Circ. Res. 86:1 (2000), 4–5.
181. [181] Ha, J.M., Jin, S.Y., Lee, H.S., Shin, H.K., Lee, D.H., Song, S.H., Kim, C.D., Bae, S.S., Regulation of retinal angiogenesis by endothelial nitric oxide synthase signaling pathway. Korean J. Physiol. Pharm. 20:5 (2016), 533–538.
182. [182] Chiu, W.C., Chiou, T.J., Chung, M.J., Chiang, A.N., beta2-Glycoprotein I Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis by Suppressing the Phosphorylation of Extracellular Signal-Regulated Kinase 1/2, Akt, and Endothelial Nitric Oxide Synthase. PLoS One, 11(8), 2016, e0161950.
183. [183] Chen, Z., Zhang, L., Yu, J., Chen, L., Zhou, B., Identification of resveratrol derivative 3,3',4,4',5,5'-hexamethoxy- trans-stilbene as a novel pro-angiogenic small-molecule compound. Eur. J. Pharm. 791 (2016), 185–194.
184. [184] Wihastuti, T.A., Sargowo, D., Tjokroprawiro, A., Permatasari, N., Widodo, M.A., Soeharto, S., Vasa vasorum anti-angiogenesis through H(2)O(2), HIF-1alpha, NF-kappaB, and iNOS inhibition by mangosteen pericarp ethanolic extract (Garcinia mangostana Linn) in hypercholesterol-diet-given Rattus norvegicus Wistar strain. Vasc. Health Risk Manag. 10 (2014), 523–531.
185. [185] Lee, J., Bae, E.H., Ma, S.K., Kim, S.W., Altered Nitric Oxide System in Cardiovascular and Renal Diseases. Chonnam Med. J. 52:2 (2016), 81–90.
186. [186] Kofler, N., Simons, M., The expanding role of neuropilin: regulation of transforming growth factor-beta and platelet-derived growth factor signaling in the vasculature. Curr. Opin. Hematol. 23:3 (2016), 260–267.
187. [187] Leveen, P., Pekny, M., Gebre-Medhin, S., Swolin, B., Larsson, E., Betsholtz, C., Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 8:16 (1994), 1875–1887.
188. [188] Soriano, P., Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev. 8:16 (1994), 1888–1896.
189. [189] Lindahl, P., Johansson, B.R., Leveen, P., Betsholtz, C., Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:5323 (1997), 242–245.
190. [190] Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A., Betsholtz, C., Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:14 (1999), 3047–3055.
191. [191] Lassila, M., Allen, T.J., Cao, Z., Thallas, V., Jandeleit-Dahm, K.A., Candido, R., Cooper, M.E., Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb. Vasc. Biol. 24:5 (2004), 935–942.
192. [192] Chowdhury, M., Ghosh, J., Slevin, M., Smyth, J.V., Alexander, M.Y., Serracino-Inglott, F., A comparative study of carotid atherosclerotic plaque microvessel density and angiogenic growth factor expression in symptomatic versus asymptomatic patients. Eur. J. Vasc. Endovasc. Surg. 39:4 (2010), 388–395.
193. [193] Pelisek, J., Well, G., Reeps, C., Rudelius, M., Kuehnl, A., Culmes, M., Poppert, H., Zimmermann, A., Berger, H., Eckstein, H.H., Neovascularization and angiogenic factors in advanced human carotid artery stenosis. Circ. J. 76:5 (2012), 1274–1282.
194. [194] Pepper, M.S., Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 8:1 (1997), 21–43.
195. [195] Ferrari, G., Cook, B.D., Terushkin, V., Pintucci, G., Mignatti, P., Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J. Cell Physiol. 219:2 (2009), 449–458.
196. [196] Hirschi, K.K., Rohovsky, S.A., D'Amore, P.A., PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol. 141:3 (1998), 805–814.
197. [197] Ferrari, G., Pintucci, G., Seghezzi, G., Hyman, K., Galloway, A.C., Mignatti, P., VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc. Natl. Acad. Sci. USA 103:46 (2006), 17260–17265.
198. [198] Javerzat, S., Auguste, P., Bikfalvi, A., The role of fibroblast growth factors in vascular development. Trends Mol. Med. 8:10 (2002), 483–489.
199. [199] Dreux, A.C., Lamb, D.J., Modjtahedi, H., Ferns, G.A., The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 186:1 (2006), 38–53.
200. [200] Mehta, V.B., Zhou, Y., Radulescu, A., Besner, G.E., HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors 26:6 (2008), 301–315.
201. [201] Carvalho, M.I., Guimaraes, M.J., Pires, I., Prada, J., Silva-Carvalho, R., Lopes, C., Queiroga, F.L., EGFR and microvessel density in canine malignant mammary tumours. Res. Vet. Sci. 95:3 (2013), 1094–1099.
202. [202] Li, Y.B., Wang, Z.Q., Yan, X., Chen, M.W., Bao, J.L., Wu, G.S., Ge, Z.M., Zhou, D.M., Wang, Y.T., Li, R.T., IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities. Cancer Lett. 340:1 (2013), 88–96.
203. [203] Khong, T.L., Thairu, N., Larsen, H., Dawson, P.M., Kiriakidis, S., Paleolog, E.M., Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. BMC Cancer, 13, 2013, 518.
204. [204] Chan, H., Pitson, S.M., Post-translational regulation of sphingosine kinases. Biochim Biophys. Acta 1831:1 (2013), 147–156.
205. [205] Mitra, P., Oskeritzian, C.A., Payne, S.G., Beaven, M.A., Milstien, S., Spiegel, S., Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc. Natl. Acad. Sci. USA 103:44 (2006), 16394–16399.
206. [206] Fukuhara, S., Simmons, S., Kawamura, S., Inoue, A., Orba, Y., Tokudome, T., Sunden, Y., Arai, Y., Moriwaki, K., Ishida, J., Uemura, A., Kiyonari, H., Abe, T., Fukamizu, A., Hirashima, M., Sawa, H., Aoki, J., Ishii, M., Mochizuki, N., The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J. Clin. Invest 122:4 (2012), 1416–1426.
207. [207] Spiegel, S., Milstien, S., Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4:5 (2003), 397–407.
208. [208] Leclercq, T.M., Pitson, S.M., Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. IUBMB Life 58:8 (2006), 467–472.
209. [209] Maceyka, M., Harikumar, K.B., Milstien, S., Spiegel, S., Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 22:1 (2012), 50–60.
210. [210] Proia, R.L., Hla, T., Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J. Clin. Invest 125:4 (2015), 1379–1387.
211. [211] Kono, M., Mi, Y., Liu, Y., Sasaki, T., Allende, M.L., Wu, Y.P., Yamashita, T., Proia, R.L., The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J. Biol. Chem. 279:28 (2004), 29367–29373.
212. [212] Kluk, M.J., Hla, T., Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys. Acta 1582:1–3 (2002), 72–80.
213. [213] Mazurais, D., Robert, P., Gout, B., Berrebi-Bertrand, I., Laville, M.P., Calmels, T., Cell type-specific localization of human cardiac S1P receptors. J. Histochem. Cytochem. 50:5 (2002), 661–670.
214. [214] Yonesu, K., Nakamura, T., Mizuno, Y., Suzuki, C., Nagayama, T., Satoh, S., Nara, F., A novel sphingosine-1-phosphate receptor 1 antagonist prevents the proliferation and relaxation of vascular endothelial cells by sphingosine-1-phosphate. Biol. Pharm. Bull. 33:9 (2010), 1500–1505.
215. [215] Tanimoto, T., Jin, Z.G., Berk, B.C., Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J. Biol. Chem. 277:45 (2002), 42997–43001.
216. [216] Skoura, A., Hla, T., Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc. Res. 82:2 (2009), 221–228.
217. [217] Adada, M., Canals, D., Hannun, Y.A., Obeid, L.M., Sphingosine-1-phosphate receptor 2. FEBS J. 280:24 (2013), 6354–6366.
218. [218] Shimizu, T., De Wispelaere, A., Winkler, M., D'Souza, T., Caylor, J., Chen, L., Dastvan, F., Deou, J., Cho, A., Larena-Avellaneda, A., Reidy, M., Daum, G., Sphingosine-1-phosphate receptor 3 promotes neointimal hyperplasia in mouse iliac-femoral arteries. Arterioscler Thromb. Vasc. Biol. 32:4 (2012), 955–961.
219. [219] Kimura, T., Watanabe, T., Sato, K., Kon, J., Tomura, H., Tamama, K., Kuwabara, A., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., Okajima, F., Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem. J. 348:Pt 1 (2000), 71–76.
220. [220] Moreno, P.R., Purushothaman, K.R., Zias, E., Sanz, J., Fuster, V., Neovascularization in human atherosclerosis. Curr. Mol. Med 6:5 (2006), 457–477.
221. [221] Jeziorska, M., Woolley, D.E., Neovascularization in early atherosclerotic lesions of human carotid arteries: its potential contribution to plaque development. Hum. Pathol. 30:8 (1999), 919–925.
222. [222] Kwon, T.G., Lerman, L.O., Lerman, A., The vasa vasorum in atherosclerosis: the vessel within the vascular wall. J. Am. Coll. Cardiol. 65:23 (2015), 2478–2480.
223. [223] Fang, L., Choi, S.H., Baek, J.S., Liu, C., Almazan, F., Ulrich, F., Wiesner, P., Taleb, A., Deer, E., Pattison, J., Torres-Vazquez, J., Li, A.C., Miller, Y.I., Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature 498:7452 (2013), 118–122.
224. [224] Goldstein, J.L., Brown, M.S., A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161:1 (2015), 161–172.
225. [225] Infante, R.E., Wang, M.L., Radhakrishnan, A., Kwon, H.J., Brown, M.S., Goldstein, J.L., NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc. Natl. Acad. Sci. USA 105:40 (2008), 15287–15292.
226. [226] Rosenson, R.S., Brewer, H.B. Jr., Davidson, W.S., Fayad, Z.A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.C., Phillips, M.C., Rader, D.J., Remaley, A.T., Rothblat, G.H., Tall, A.R., Yvan-Charvet, L., Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125:15 (2012), 1905–1919.
227. [227] Casalou, C., Costa, A., Carvalho, T., Gomes, A.L., Zhu, Z., Wu, Y., Dias, S., Cholesterol regulates VEGFR-1 (FLT-1) expression and signaling in acute leukemia cells. Mol. Cancer Res. 9:2 (2011), 215–224.
228. [228] Santibanez, J.F., Blanco, F.J., Garrido-Martin, E.M., Sanz-Rodriguez, F., del Pozo, M.A., Bernabeu, C., Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae. Cardiovasc. Res. 77:4 (2008), 791–799.
229. [229] Razani, B., Engelman, J.A., Wang, X.B., Schubert, W., Zhang, X.L., Marks, C.B., Macaluso, F., Russell, R.G., Li, M., Pestell, R.G., Di Vizio, D., Hou, H. Jr., Kneitz, B., Lagaud, G., Christ, G.J., Edelmann, W., Lisanti, M.P., Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276:41 (2001), 38121–38138.
230. [230] Pavlides, S., Gutierrez-Pajares, J.L., Danilo, C., Lisanti, M.P., Frank, P.G., Atherosclerosis, caveolae and caveolin-1. Adv. Exp. Med. Biol. 729 (2012), 127–144.
231. [231] Frank, P.G., Lee, H., Park, D.S., Tandon, N.N., Scherer, P.E., Lisanti, M.P., Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb. Vasc. Biol. 24:1 (2004), 98–105.
232. [232] Van Belle, E., Rivard, A., Chen, D., Silver, M., Bunting, S., Ferrara, N., Symes, J.F., Bauters, C., Isner, J.M., Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 96:8 (1997), 2667–2674.
233. −/− mice. Circulation 99:24 (1999), 3188–3198.
234. [234] Boodhwani, M., Nakai, Y., Mieno, S., Voisine, P., Bianchi, C., Araujo, E.G., Feng, J., Michael, K., Li, J., Sellke, F.W., Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann. Thorac. Surg. 81:2 (2006), 634–641.
235. [235] Haddad, P., Dussault, S., Groleau, J., Turgeon, J., Maingrette, F., Rivard, A., Nox2-derived reactive oxygen species contribute to hypercholesterolemia-induced inhibition of neovascularization: effects on endothelial progenitor cells and mature endothelial cells. Atherosclerosis 217:2 (2011), 340–349.
236. [236] Jin, F., Hagemann, N., Brockmeier, U., Schafer, S.T., Zechariah, A., Hermann, D.M., LDL attenuates VEGF-induced angiogenesis via mechanisms involving VEGFR2 internalization and degradation following endosome-trans-Golgi network trafficking. Angiogenesis, 16, 2013, 625–637.
237. [237] Zechariah, A., ElAli, A., Hagemann, N., Jin, F., Doeppner, T.R., Helfrich, I., Mies, G., Hermann, D.M., Hyperlipidemia attenuates vascular endothelial growth factor-induced angiogenesis, impairs cerebral blood flow, and disturbs stroke recovery via decreased pericyte coverage of brain endothelial cells. Arterioscler Thromb. Vasc. Biol. 33:7 (2013), 1561–1567.
238. [238] Huang, C.Y., Lin, F.Y., Shih, C.M., Au, H.K., Chang, Y.J., Nakagami, H., Morishita, R., Chang, N.C., Shyu, K.G., Chen, J.W., Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating Rho-associated kinase pathways. Arterioscler Thromb. Vasc. Biol. 32:10 (2012), 2405–2417.
239. [239] Tall, A.R., Yvan-Charvet, L., Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15:2 (2015), 104–116.
240. [240] Dandapat, A., Hu, C., Sun, L., Mehta, J.L., Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler Thromb. Vasc. Biol. 27:11 (2007), 2435–2442.
241. [241] Yu, S., Wong, S.L., Lau, C.W., Huang, Y., Yu, C.M., Oxidized LDL at low concentration promotes in-vitro angiogenesis and activates nitric oxide synthase through PI3K/Akt/eNOS pathway in human coronary artery endothelial cells. Biochem Biophys. Res Commun. 407:1 (2011), 44–48.
242. [242] Khaidakov, M., Mitra, S., Wang, X., Ding, Z., Bora, N., Lyzogubov, V., Romeo, F., Schichman, S.A., Mehta, J.L., Large impact of low concentration oxidized LDL on angiogenic potential of human endothelial cells: a microarray study. PLoS One, 7(10), 2012, e47421.
243. [243] Camare, C., Trayssac, M., Garmy-Susini, B., Mucher, E., Sabbadini, R., Salvayre, R., Negre-Salvayre, A., Oxidized LDL-induced angiogenesis involves sphingosine 1-phosphate: prevention by anti-S1P antibody. Br. J. Pharm. 172:1 (2015), 106–118.
244. [244] Bochkov, V.N., Philippova, M., Oskolkova, O., Kadl, A., Furnkranz, A., Karabeg, E., Afonyushkin, T., Gruber, F., Breuss, J., Minchenko, A., Mechtcheriakova, D., Hohensinner, P., Rychli, K., Wojta, J., Resink, T., Erne, P., Binder, B.R., Leitinger, N., Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ. Res. 99:8 (2006), 900–908.
245. [245] Hutter, R., Speidl, W.S., Valdiviezo, C., Sauter, B., Corti, R., Fuster, V., Badimon, J.J., Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1alpha activation: a novel aspect of angiogenesis in atherosclerosis. J. Cardiovasc Transl. Res. 6:4 (2013), 558–569.
246. [246] Shatrov, V.A., Sumbayev, V.V., Zhou, J., Brune, B., Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood 101:12 (2003), 4847–4849.
247. [247] Camare, C., Auge, N., Pucelle, M., Saint-Lebes, B., Grazide, M.H., Negre-Salvayre, A., Salvayre, R., The neutral sphingomyelinase-2 is involved in angiogenic signaling triggered by oxidized LDL. Free Radic. Biol. Med. 93 (2016), 204–216.
248. [248] Igarashi, J., Miyoshi, M., Hashimoto, T., Kubota, Y., Kosaka, H., Hydrogen peroxide induces S1P1 receptors and sensitizes vascular endothelial cells to sphingosine 1-phosphate, a platelet-derived lipid mediator. Am. J. Physiol. Cell Physiol. 292:2 (2007), C740–C748.
249. [249] C. Cinq-Frais, C. Coatrieux, M.H. Grazide, Y.A. Hannun, A. Negre-Salvayre, R. Salvayre, N. Auge, A signaling cascade mediated by ceramide, src and PDGFRbeta coordinates the activation of the redox-sensitive neutral sphingomyelinase-2 and sphingosine kinase-1, Biochim Biophys Acta, 1831(8), 2013, pp.1344–1356.
250. [250] Murugesan, G., Chisolm, G.M., Fox, P.L., Oxidized low density lipoprotein inhibits the migration of aortic endothelial cells in vitro. J. Cell Biol. 120:4 (1993), 1011–1019.
251. [251] Chen, C.H., Jiang, W., Via, D.P., Luo, S., Li, T.R., Lee, Y.T., Henry, P.D., Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 101:2 (2000), 171–177.
252. [252] Amaral, J., Lee, J.W., Chou, J., Campos, M.M., Rodriguez, I.R., 7-Ketocholesterol induces inflammation and angiogenesis in vivo: a novel rat model. PLoS One, 8(2), 2013, e56099.
253. [253] Schoors, S., Bruning, U., Missiaen, R., Queiroz, K.C., Borgers, G., Elia, I., Zecchin, A., Cantelmo, A.R., Christen, S., Goveia, J., Heggermont, W., Godde, L., Vinckier, S., Van Veldhoven, P.P., Eelen, G., Schoonjans, L., Gerhardt, H., Dewerchin, M., Baes, M., De Bock, K., Ghesquiere, B., Lunt, S.Y., Fendt, S.M., Carmeliet, P., Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520:7546 (2015), 192–197.
254. [254] Negre-Salvayre, A., Coatrieux, C., Ingueneau, C., Salvayre, R., Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br. J. Pharm. 153:1 (2008), 6–20.
255. [255] Fleming, I., The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease. Pharm. Rev. 66:4 (2014), 1106–1140.
256. [256] Watson, A.D., Leitinger, N., Navab, M., Faull, K.F., Horkko, S., Witztum, J.L., Palinski, W., Schwenke, D., Salomon, R.G., Sha, W., Subbanagounder, G., Fogelman, A.M., Berliner, J.A., Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272:21 (1997), 13597–13607.
257. [257] Uchida, K., Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 28:12 (2000), 1685–1696.
258. [258] Negre-Salvayre, A., Auge, N., Ayala, V., Basaga, H., Boada, J., Brenke, R., Chapple, S., Cohen, G., Feher, J., Grune, T., Lengyel, G., Mann, G.E., Pamplona, R., Poli, G., Portero-Otin, M., Riahi, Y., Salvayre, R., Sasson, S., Serrano, J., Shamni, O., Siems, W., Siow, R.C., Wiswedel, I., Zarkovic, K., Zarkovic, N., Pathological aspects of lipid peroxidation. Free Radic. Res. 44:10 (2010), 1125–1171.
259. [259] Escargueil-Blanc, I., Salvayre, R., Vacaresse, N., Jurgens, G., Darblade, B., Arnal, J.F., Parthasarathy, S., Negre-Salvayre, A., Mildly oxidized LDL induces activation of platelet-derived growth factor beta-receptor pathway. Circulation 104:15 (2001), 1814–1821.
260. [260] Robbesyn, F., Auge, N., Vindis, C., Cantero, A.V., Barbaras, R., Negre-Salvayre, A., Salvayre, R., High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb. Vasc. Biol. 25:6 (2005), 1206–1212.
261. [261] Negre-Salvayre, A., Vieira, O., Escargueil-Blanc, I., Salvayre, R., Oxidized LDL and 4-hydroxynonenal modulate tyrosine kinase receptor activity. Mol. Asp. Med. 24:4–5 (2003), 251–261.
262. [262] Robino, G., Parola, M., Marra, F., Caligiuri, A., De Franco, R.M., Zamara, E., Bellomo, G., Gentilini, P., Pinzani, M., Dianzani, M.U., Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J. Biol. Chem. 275:51 (2000), 40561–40567.
263. [263] Vindis, C., Escargueil-Blanc, I., Elbaz, M., Marcheix, B., Grazide, M.H., Uchida, K., Salvayre, R., Negre-Salvayre, A., Desensitization of platelet-derived growth factor receptor-beta by oxidized lipids in vascular cells and atherosclerotic lesions: prevention by aldehyde scavengers. Circ. Res. 98:6 (2006), 785–792.
264. [264] Edirisinghe, I., Rahman, I., Cigarette smoke-mediated oxidative stress, shear stress, and endothelial dysfunction: role of VEGFR2. Ann. NY Acad. Sci. 1203 (2010), 66–72.
265. [265] Fang, L., Liu, C., Miller, Y.I., Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis. Transl. Res. 163:2 (2014), 99–108.
266. [266] Tatematsu, S., Francis, S.A., Natarajan, P., Rader, D.J., Saghatelian, A., Brown, J.D., Michel, T., Plutzky, J., Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler Thromb. Vasc. Biol. 33:8 (2013), 1788–1794.
267. [267] Zhu, L., Fang, L., AIBP, Novel, A., Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis. Methodist Debakey Cardiovasc. J. 11:3 (2015), 160–165.
268. [268] Parham, K.A., Zebol, J.R., Tooley, K.L., Sun, W.Y., Moldenhauer, L.M., Cockshell, M.P., Gliddon, B.L., Moretti, P.A., Tigyi, G., Pitson, S.M., Bonder, C.S., Sphingosine 1-phosphate is a ligand for peroxisome proliferator-activated receptor-gamma that regulates neoangiogenesis. FASEB J. 29:9 (2015), 3638–3653.
269. [269] Ho-Tin-Noe, B., Le Dall, J., Gomez, D., Louedec, L., Vranckx, R., El-Bouchtaoui, M., Legres, L., Meilhac, O., Michel, J.B., Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ. Res. 109:9 (2011), 1003–1014.
270. [270] Harrison, D., Griendling, K.K., Landmesser, U., Hornig, B., Drexler, H., Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 91:3A (2003), 7A–11A.
271. [271] Frey, R.S., Ushio-Fukai, M., Malik, A.B., NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid. Redox Signal 11:4 (2009), 791–810.
272. [272] Brown, D.I., Griendling, K.K., Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ. Res. 116:3 (2015), 531–549.
273. [273] Salvayre, R., Negre-Salvayre, A., Camare, C., Oxidative theory of atherosclerosis and antioxidants. Biochimie 125 (2016), 281–296.
274. [274] Ruef, J., Hu, Z.Y., Yin, L.Y., Wu, Y., Hanson, S.R., Kelly, A.B., Harker, L.A., Rao, G.N., Runge, M.S., Patterson, C., Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Circ. Res. 81:1 (1997), 24–33.
275. [275] Bir, S.C., Shen, X., Kavanagh, T.J., Kevil, C.G., Pattillo, C.B., Control of angiogenesis dictated by picomolar superoxide levels. Free Radic. Biol. Med. 63 (2013), 135–142.
276. [276] Kim, Y.W., Byzova, T.V., Oxidative stress in angiogenesis and vascular disease. Blood 123:5 (2014), 625–631.
277. [277] Ross, R., Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340:2 (1999), 115–126.
278. [278] Leclercq, A., Houard, X., Philippe, M., Ollivier, V., Sebbag, U., Meilhac, O., Michel, J.B., Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J. Leukoc. Biol. 82:6 (2007), 1420–1429.
279. [279] Arroyo, A.G., Iruela-Arispe, M.L., Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc. Res. 86:2 (2010), 226–235.
280. [280] Libby, P., Ridker, P.M., Hansson, G.K., Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347 (2011), 317–325.
281. [281] Pardali, E., Goumans, M.J., ten Dijke, P., Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 20:9 (2010), 556–567.
282. [282] Ghajar, C.M., George, S.C., Putnam, A.J., Matrix metalloproteinase control of capillary morphogenesis. Crit. Rev. Eukaryot. Gene Expr. 18:3 (2008), 251–278.
283. [283] De Smet, F., Segura, I., De Bock, K., Hohensinner, P.J., Carmeliet, P., Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb. Vasc. Biol. 29:5 (2009), 639–649.
284. [284] Karagiannis, E.D., Popel, A.S., Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. J. Theor. Biol. 238:1 (2006), 124–145.
285. [285] Auge, N., Maupas-Schwalm, F., Elbaz, M., Thiers, J.C., Waysbort, A., Itohara, S., Krell, H.W., Salvayre, R., Negre-Salvayre, A., Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation 110:5 (2004), 571–578.
286. [286] Langlois, S., Gingras, D., Beliveau, R., Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103:8 (2004), 3020–3028.
287. [287] Annabi, B., Thibeault, S., Lee, Y.T., Bousquet-Gagnon, N., Eliopoulos, N., Barrette, S., Galipeau, J., Beliveau, R., Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Exp. Hematol. 31:7 (2003), 640–649.
288. [288] Raab, S., Plate, K.H., Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol. 113:6 (2007), 607–626.
289. [289] Yana, I., Sagara, H., Takaki, S., Takatsu, K., Nakamura, K., Nakao, K., Katsuki, M., Taniguchi, S., Aoki, T., Sato, H., Weiss, S.J., Seiki, M., Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell Sci. 120:Pt 9 (2007), 1607–1614.
290. [290] Libby, P., Folco, E., Tension in the plaque: hypoxia modulates metabolism in atheroma. Circ. Res. 109:10 (2011), 1100–1102.
291. [291] Michel, J.B., Virmani, R., Arbustini, E., Pasterkamp, G., Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur. Heart J. 32:16 (2011), 1977–1985 (1985a, 1985b, 1985c).
292. [292] Khurana, R., Simons, M., Martin, J.F., Zachary, I.C., Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112:12 (2005), 1813–1824.
293. [293] McCarthy, M.J., Loftus, I.M., Thompson, M.M., Jones, L., London, N.J., Bell, P.R., Naylor, A.R., Brindle, N.P., Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J. Vasc. Surg. 30:2 (1999), 261–268.
294. [294] Gao, P., Chen, Z.Q., Bao, Y.H., Jiao, L.Q., Ling, F., Correlation between carotid intraplaque hemorrhage and clinical symptoms: systematic review of observational studies. Stroke 38:8 (2007), 2382–2390.
295. [295] Kolodgie, F.D., Burke, A.P., Nakazawa, G., Cheng, Q., Xu, X., Virmani, R., Free cholesterol in atherosclerotic plaques: where does it come from. Curr. Opin. Lipido. 18:5 (2007), 500–507.
296. [296] Abela, G.S., Aziz, K., Vedre, A., Pathak, D.R., Talbott, J.D., Dejong, J., Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am. J. Cardiol. 103:7 (2009), 959–968.
297. [297] Duewell, P., Kono, H., Rayner, K.J., Sirois, C.M., Vladimer, G., Bauernfeind, F.G., Abela, G.S., Franchi, L., Nunez, G., Schnurr, M., Espevik, T., Lien, E., Fitzgerald, K.A., Rock, K.L., Moore, K.J., Wright, S.D., Hornung, V., Latz, E., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:7293 (2010), 1357–1361.
298. [298] Rajamaki, K., Lappalainen, J., Oorni, K., Valimaki, E., Matikainen, S., Kovanen, P.T., Eklund, K.K., Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One, 5(7), 2010, e11765.
299. [299] Tziakas, D.N., Kaski, J.C., Chalikias, G.K., Romero, C., Fredericks, S., Tentes, I.K., Kortsaris, A.X., Hatseras, D.I., Holt, D.W., Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability?. J. Am. Coll. Cardiol. 49:21 (2007), 2081–2089.
300. [300] Tziakas, D.N., Chalikias, G.K., Stakos, D., Tentes, I.K., Chatzikyriakou, S.V., Mitrousi, K., Kortsaris, A.X., Boudoulas, H., Kaski, J.C., Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease. Coron. Artery Dis. 19:8 (2008), 583–590.
301. [301] Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., Witztum, J.L., Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:14 (1989), 915–924.
302. [302] Esterbauer, H., Dieber-Rotheneder, M., Waeg, G., Striegl, G., Jurgens, G., Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem. Res. Toxicol. 3:2 (1990), 77–92.
303. [303] Stocker, R., Keaney, J.F. Jr., Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84:4 (2004), 1381–1478.
304. [304] Yunoki, K., Naruko, T., Komatsu, R., Ehara, S., Shirai, N., Sugioka, K., Nakagawa, M., Kitabayashi, C., Ikura, Y., Itoh, A., Kusano, K., Ohe, T., Haze, K., Becker, A.E., Ueda, M., Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes. Eur. Heart J. 30:15 (2009), 1844–1852.
305. [305] Nagy, E., Eaton, J.W., Jeney, V., Soares, M.P., Varga, Z., Galajda, Z., Szentmiklosi, J., Mehes, G., Csonka, T., Smith, A., Vercellotti, G.M., Balla, G., Balla, J., Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb. Vasc. Biol. 30:7 (2010), 1347–1353.
306. [306] Chen, Y.C., Bui, A.V., Diesch, J., Manasseh, R., Hausding, C., Rivera, J., Haviv, I., Agrotis, A., Htun, N.M., Jowett, J., Hagemeyer, C.E., Hannan, R.D., Bobik, A., Peter, K., A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. Circ. Res. 113:3 (2013), 252–265.
307. [307] Kolb, S., Vranckx, R., Huisse, M.G., Michel, J.B., Meilhac, O., The phosphatidylserine receptor mediates phagocytosis by vascular smooth muscle cells. J. Pathol. 212:3 (2007), 249–259.
308. [308] Kalet-Litman, S., Moreno, P.R., Levy, A.P., The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis 209:1 (2010), 28–31.
309. [309] Levy, A.P., Asleh, R., Blum, S., Levy, N.S., Miller-Lotan, R., Kalet-Litman, S., Anbinder, Y., Lache, O., Nakhoul, F.M., Asaf, R., Farbstein, D., Pollak, M., Soloveichik, Y.Z., Strauss, M., Alshiek, J., Livshits, A., Schwartz, A., Awad, H., Jad, K., Goldenstein, H., Haptoglobin: basic and clinical aspects. Antioxid. Redox Signal 12:2 (2010), 293–304.
310. [310] Sugiyama, S., Okada, Y., Sukhova, G.K., Virmani, R., Heinecke, J.W., Libby, P., Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 158:3 (2001), 879–891.
311. [311] van der Veen, B.S., de Winther, M.P., Heeringa, P., Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid. Redox Signal 11:11 (2009), 2899–2937.
312. [312] Leclercq, A., Houard, X., Loyau, S., Philippe, M., Sebbag, U., Meilhac, O., Michel, J.B., Topology of protease activities reflects atherothrombotic plaque complexity. Atherosclerosis 191:1 (2007), 1–10.
313. [313] Mansilla, S., Boulaftali, Y., Venisse, L., Arocas, V., Meilhac, O., Michel, J.B., Jandrot-Perrus, M., Bouton, M.C., Macrophages and platelets are the major source of protease nexin-1 in human atherosclerotic plaque. Arterioscler Thromb. Vasc. Biol. 28:10 (2008), 1844–1850.
314. [314] Bouhlel, M.A., Derudas, B., Rigamonti, E., Dievart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., Staels, B., Chinetti-Gbaguidi, G., PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6:2 (2007), 137–143.
315. [315] Boyle, J.J., Harrington, H.A., Piper, E., Elderfield, K., Stark, J., Landis, R.C., Haskard, D.O., Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am. J. Pathol. 174:3 (2009), 1097–1108.
316. [316] Simonini, A., Moscucci, M., Muller, D.W., Bates, E.R., Pagani, F.D., Burdick, M.D., Strieter, R.M., IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 101:13 (2000), 1519–1526.
317. [317] Griffith, E.C., Su, Z., Niwayama, S., Ramsay, C.A., Chang, Y.H., Liu, J.O., Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl. Acad. Sci. USA 95:26 (1998), 15183–15188.
318. [318] Winter, P.M., Neubauer, A.M., Caruthers, S.D., Harris, T.D., Robertson, J.D., Williams, T.A., Schmieder, A.H., Hu, G., Allen, J.S., Lacy, E.K., Zhang, H., Wickline, S.A., Lanza, G.M., Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb. Vasc. Biol. 26:9 (2006), 2103–2109.
319. −/− mice by inhibiting LDL oxidation via nitric oxide. Circ. Res. 104:12 (2009), 1333–1336.
320. [320] Wilson, S.H., Herrmann, J., Lerman, L.O., Holmes, D.R. Jr., Napoli, C., Ritman, E.L., Lerman, A., Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 105:4 (2002), 415–418.
321. [321] Cheungpasitporn, W., Chebib, F.T., Cornell, L.D., Brodin, M.L., Nasr, S.H., Schinstock, C.A., Stegall, M.D., Amer, H., Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts. Transplantation 99:11 (2015), 2382–2386.
322. [322] Maurea, N., Coppola, C., Piscopo, G., Galletta, F., Riccio, G., Esposito, E., De Lorenzo, C., De Laurentiis, M., Spallarossa, P., Mercuro, G., Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J. Cardiovasc Med. (Hagerstown) 17:Suppl 1 (2016), S19–S26.